Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. Common Stock (LXEO) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · LXEO · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
26
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Lexeo Therapeutics, Inc. Common Stock insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
LXEO insider buying and selling by quarter
LXEO insider selling · LXEO insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · LXEO ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
LXEO executive sell shares · LXEO board member insider trading · LXEO insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 18, 2026 | Otero Jose Manuel COO | Sale | 1,302 | $7K | Form 4 |
| May 18, 2026 | Townsend Richard Nolan CEO · Director | Sale | 3,342 | $17K | Form 4 |
| Apr 6, 2026 | Townsend Richard Nolan CEO · Director | Sale | 55,000 | $313K | Form 4 |
| Mar 13, 2026 | Townsend Richard Nolan CEO · Director | Award | 2,623 | $7K | Form 4 |
| Mar 13, 2026 | Otero Jose Manuel COO | Award | 5,930 | $16K | Form 4 |
| Feb 18, 2026 | Otero Jose Manuel COO | Sale | 3,016 | $19K | Form 4 |
| Feb 18, 2026 | Townsend Richard Nolan CEO · Director | Sale | 10,173 | $65K | Form 4 |
| Feb 13, 2026 | Bhalla Narinder Pal Chief Medical Officer | Award | 49,500 | — | Form 4 |
| Feb 4, 2026 | Townsend Richard Nolan CEO · Director | Award | 161,665 | — | Form 4 |
| Feb 4, 2026 | Otero Jose Manuel COO | Award | 65,000 | — | Form 4 |
| Feb 4, 2026 | Tamayo Louis Edward CFO | Award | 44,665 | — | Form 4 |
| Nov 18, 2025 | Townsend Richard Nolan CEO · Director | Sale | 1,127 | $10K | Form 4 |
| Nov 18, 2025 | Adler Eric Chief Medical Officer | Sale | 615 | $6K | Form 4 |
| Nov 18, 2025 | See Tai Sandi Chief Development Officer | Sale | 386 | $4K | Form 4 |
| Nov 18, 2025 | Robertson Jenny Chief Legal Officer | Sale | 549 | $5K | Form 4 |
| Aug 18, 2025 | Otero Jose Manuel Chief Technical Officer | Sale | 721 | $7K | Form 4 |
| Oct 15, 2025 | See Tai Sandi Chief Development Officer | Award | 10,890 | — | Form 4 |
| Oct 17, 2025 | See Tai Sandi Chief Development Officer | Sale | 3,844 | $34K | Form 4 |
| Oct 17, 2025 | See Tai Sandi Chief Development Officer | Sale | 44 | $421 | Form 4 |
| Oct 15, 2025 | Robertson Jenny Chief Legal Officer | Award | 9,900 | — | Form 4 |
| Oct 17, 2025 | Robertson Jenny Chief Legal Officer | Sale | 3,486 | $31K | Form 4 |
| Oct 17, 2025 | Robertson Jenny Chief Legal Officer | Sale | 40 | $382 | Form 4 |
| Oct 15, 2025 | Otero Jose Manuel Chief Technical Officer | Award | 5,940 | — | Form 4 |
| Oct 17, 2025 | Otero Jose Manuel Chief Technical Officer | Sale | 2,091 | $19K | Form 4 |
| Oct 17, 2025 | Otero Jose Manuel Chief Technical Officer | Sale | 24 | $229 | Form 4 |
Townsend Richard Nolan
CEO · Director
Date
May 18
Shares
3,342
Price
$5.06
Value
$17K
Townsend Richard Nolan
CEO · Director
Date
Apr 6
Shares
55,000
Price
$5.69
Value
$313K
Townsend Richard Nolan
CEO · Director
Date
Mar 13
Shares
2,623
Price
$2.64
Value
$7K
Townsend Richard Nolan
CEO · Director
Date
Feb 18
Shares
10,173
Price
$6.38
Value
$65K
Bhalla Narinder Pal
Chief Medical Officer
Date
Feb 13
Shares
49,500
Price
—
Value
—
Townsend Richard Nolan
CEO · Director
Date
Nov 18
Shares
1,127
Price
$9.27
Value
$10K
See Tai Sandi
Chief Development Officer
Date
Nov 18
Shares
386
Price
$9.27
Value
$4K
Otero Jose Manuel
Chief Technical Officer
Date
Aug 18
Shares
721
Price
$9.27
Value
$7K
See Tai Sandi
Chief Development Officer
Date
Oct 17
Shares
3,844
Price
$8.94
Value
$34K
See Tai Sandi
Chief Development Officer
Date
Oct 17
Shares
44
Price
$9.56
Value
$421
Robertson Jenny
Chief Legal Officer
Date
Oct 17
Shares
3,486
Price
$8.94
Value
$31K
Otero Jose Manuel
Chief Technical Officer
Date
Oct 15
Shares
5,940
Price
—
Value
—
Otero Jose Manuel
Chief Technical Officer
Date
Oct 17
Shares
2,091
Price
$8.94
Value
$19K
Otero Jose Manuel
Chief Technical Officer
Date
Oct 17
Shares
24
Price
$9.56
Value
$229
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About LXEO insider trading
LXEO insider trades
Lexeo Therapeutics, Inc. Common Stock (LXEO) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Townsend Richard Nolan (CEO · Director), Otero Jose Manuel (COO), Adler Eric (Chief Medical Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. LXEO insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Lexeo Therapeutics, Inc. Common Stock's institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
LXEO insider trading · 5 questionsThe insiders of Lexeo Therapeutics, Inc. Common Stock (LXEO) include executives and directors such as Townsend Richard Nolan (CEO · Director), Otero Jose Manuel (COO), Adler Eric (Chief Medical Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026